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World Tuberculosis Day 2021 Theme — ‘The Clock is Ticking’ — and
the world is running out of time to deliver the United Nations
General Assembly commitments to End TB due to the COVID-19
pandemic
On March 24th 1882 Koch’s announcement in Berlin of the
discovery of the microbial cause of tuberculosis (TB), Mycobacteri-
um tuberculosis, heralded a major breakthrough, bringing hope for
a devastating disease which at that time caused the death of one in
seven people in Europe and the Americas. (Wallstedt and Maeurer,
2015). One hundred and twenty years later, and despite the
availability of effective treatment for the past 6 decades, 1.4 million
people die of TB annually (WHO, 2021a). Over the past 15 months,
the unprecedented COVID-19 pandemic has disrupted health
services globally (Cilloni et al., 2020) and has negatively impacted
on gains being made in global TB control efforts to achieve End TB
targets (Sahu et al., 2020; STOP TB, 2019).
The theme of this year’s World TB Day March 24th, 2021, ‘The
Clock is Ticking’ (WHO, 2021b), conveys the sense of urgency that
the world is running out of time to deliver the commitments to End
TB made by global leaders at the United Nations General Assembly
high level meeting on TB (UNGA, 2018). This theme is particularly
appropriate and critical in light of the devastating COVID-19
pandemic which is currently the top killer from an infectious
disease globally, with TB now being shifted to second place (WHO,
2021a; WHO, 2021c). Since the end of December, 2019, when the
WHO was made aware of several cases of atypical pneumonia in
Wuhan, China, caused by the novel severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), as of March 15th 2021,
there have been 119,603,761 confirmed COVID-19 cases, with
2,649,722 deaths, reported to WHO (WHO, 2021c).
In commemoration of World TB Day March 24th, 2021, the
International Journal of Infectious Diseases is once again publish-
ing a specific TB Theme issue of 18 articles covering a range of
topics.
The October 2020 WHO Global TB report and the United Nations
(UN) Secretary-General’s 2020 progress report on TB, are reviewed
by Chakaya et al. (2021). They reflect on current TB control
strategies in light of the United Nations (UN) targets set in the
political declaration at the September 2018 UN General Assembly
high-level meeting on TB held in New York (UNGA, 2018). Progress
in achieving TB control targets has been very slow. Globally, an
estimated 10.0 million people developed TB disease in 2019, and
unprecedented, devastating COVID-19 pandemic is affecting TB
health services, interrupting and slowing down treatment and
prevention efforts. It is anticipated that the End TB strategy target
of ending TB by 2035 will not be met. The WHO 2020 TB Report
(WHO, 2021a) states that a 50% drop in the number of people with
TB detected, could result in up to 400,000 additional TB deaths in a
year. Innovative plans are needed to maintain all TB services as well
as access to these services, in the wake of the COVID-19 pandemic
and investments in the development of low-cost rapid diagnostic
tests for both COVID-19 and TB are urgently needed. There needs to
be a rejuvenated, sustained, and concerted effort to identify and
treat ‘missing people with TB’. Governments of high TB incidence
countries need to ensure there are rapid TB diagnostic services
available in every health facility, so all TB cases can be reached.
Global health inequities that underlie differences in TB disease
burden, as well as daunting environmental health challenges, need
to be addressed by multiple approaches and sectors.
Fox et al. (2021) highlight that latent tuberculosis infection
affects one quarter of the world’s population and that despite
effective oral treatment regimens being available, scale-up and
rollout of TB preventive treatment (TPT) remains limited. They
describe strategies to support scale-up of TPT in high-prevalence
settings, where the potential benefit for affected individuals is
considerable and emphasise that patients must be at the centre of
TPT policies. Addressing health system requirements for scale-up
will be important to ensure that programs can deliver treatment
safely, efficiently and sustainably.
Nachega et al. (2021a) discuss the negative impact of COVID-19
on TB and HIV health services. They suggest approaches to mitigate
the growing burden of these colliding epidemics in sub-Saharan
Africa, which bear the highest proportions of TB and HIV cases
worldwide. The COVID-19 pandemic has added an additional
burden to already overstretched health systems, which, among
many other things, were struggling to deal with the longstanding
dual epidemics of TB and HIV.
Knipper et al. (2021) review the COVID-19 pandemic threat to
derailing health services for forcibly displaced people and migrant
populations, populations who face specific vulnerabilities placing
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opulations, and the impact of COVID-19 on TB among these
opulations. They indicate that addressing TB, COVID-19 and
igration from a syndemic perspective, not only draws systematic
ttention to comorbidity and the relevance of social and structural
ontext, but also helps to find solutions. The true reality of
yndemic interactions can only be fully understood by considering
 particular population and bio-social context and ensuring that
hey receive the comprehensive care that they need. It also
rovides avenues for strengthening and expanding the existing
nfrastructure for TB care to tackle both COVID-19 and TB in
igrants and refugees in an integrated and synergistic manner.
Over a quarter of the individuals diagnosed with TB in the
uropean Union region are born outside the EU and the proportion
as been increasing steadily. Over 50% of TB cases in Italy are
oreign born migrants. Gosce’ et al. (2021) describe the EDETECT-
B project in Italy which implemented and evaluated active TB
creening in the migrant population and their study confirmed that
arly case detection is a cost-effective intervention and that
argeted post-arrival early screening ensures that potential further
ransmission is averted.
Recurrent pulmonary TB is a growing, important and neglected
roblem affecting treated TB patients and TB health services across
he world, particularly in sub-Saharan Africa and Asia. Analyses
nd identification of differences in clinical features between
ecurrent PTB and newly diagnosed PTB may lead to improved
anagement recommendations. Nagu et al. (2021) performed a
rospective case-controlled study of clinical and imaging features
f patients with recurrent pulmonary TB (RPTB) and compared
hem with those of newly diagnosed PTB cases. They found that
emoptysis, lung parenchymal damage, and patients being older
han 45 years of age are significant features of RPTB, suggesting
hat management of TB cases should focus on risk factors for
ecurrence, and design a more holistic model of care to prevent
ong term lung injury.
Kizny Gordon et al. (2021) review the clinical and public health
tility benefits of M. tuberculosis whole genome sequencing (WGS),
ncluding provision of more rapid and complete information on
rug-resistance, detection of transmission clusters, contamination
vents, mixed infections, and to differentiate between re-infection
nd relapse. They also discuss future advances that have the
otential to change the landscape of TB diagnostics and manage-
ent, such as culture-free sequencing and surveillance of
ntimicrobial resistance to guide precision medicine approaches,
s well as some of the challenges involved. Whole genome
equencing-based differentiation between re-infection and relapse
n TB cases has important implications for public health, especially
n patients with human immunodeficiency virus (HIV) co-infection.
hanmugam et al. (2021) compared Mycobacterial Interspersed
epeat Unit (MIRU) typing and spoligotyping with WGS to
ifferentiate between relapse and re-infection and assessed the
alue of WGS to track acquired drug resistance in those with relapse
fter successful treatment. Comparing M. tuberculosis genomes,
hey found that 95% of TB recurrences in the HIV-negative cohort
ere due to relapse, while the majority of TB recurrences in the HIV-
ositive cohort were due to re-infection, highlighting the need for
ffective infection control in HIV care setting.
WGS for M. tuberculosis drug resistance detection is now
vailable in diagnostic and reference laboratories worldwide.
haracterizing novel mutations and deletions associated with drug
lineages. They demonstrated that WGS was able to capture an
additional 20% of drug resistance mutations not detected by
commercial diagnostic assays, signaling the additional value that
WGS offers over existing genotypic drug resistance assays in terms
of sensitivity.
The Bandim TBscore is a clinical score that predicts treatment
outcome in TB patients and may prove useful as an indicator of
which healthcare-seeking adults to refer for sputum smear
microcopy. Rudolf et al. (2021) conducted a stepped wedge
cluster-randomized trial at six health centers in Bissau, Guinea-
Bissau, and Gondar, Ethiopia. They conclude that it is an
implementable approach and solution to an old and yet unresolved
challenge. Using the TBscore for triage before smear microscopy
may improve case detection and decrease mortality if there is
sufficient laboratory capacity to increase sputum smears.
Marais et al. (2021) discuss new advances to close persistent
gaps in the prevention and diagnosis of childhood TB. Almost all
children estimated in the Global TB Report 2020 to have died from
TB were never diagnosed or offered TB treatment. Thus new
approaches are required to ensure that effective TB prevention
strategies are implemented and to improve the accuracy of current
and new diagnostic (rule-in and rule-out) tests. Reducing the
major gaps in TB preventive treatment (TPT) will require strong
political commitment and concerted effort, with major upscaling
of household contact investigation. While widespread roll-out of
Xpert MTB/RIF Ultra1 should be supported and could improve case
detection in young children, they caution that specimen collection
remains difficult and test sensitivity low. The use of non-sputum
specimens are essential to improve diagnostic access, but given the
limited accuracy of all available tests and the excellent tolerance of
TB drugs in children the global community may have to accept
some over-treatment using the most feasible approaches available;
if we are serious about closing the persistent case detection gap in
young children.
Zoonotic TB is evolving in an everchanging global landscape.
Despite slow reductions in the annual burden of active TB cases,
Zoonotic TB (zTB) remains a poorly monitored and poorly addressed
global burden. Kock et al. (2021) in their zoonotic TB review highlight
the higher incidence in some specific regions and countries,
especially where close association exists between growing numbers
of cattle (the major source of Mycobacterium bovis (M. bovis) and
people, many suffering from poverty and where milk or dairy
products are consumed un-pasteurized. Attention needs to be re-
focused to prevent a rapid increase in zTB disease along with
growing intensification of dairy production. Evidence of new
zoonotic mycobacterial strains such as M. orygis, especially in South
Asia and Africa warrants rapid assessment of drivers and risk, and
the development of appropriate interventions. Control of M. bovis in
cattle through early detection of infection and disease, as well as
pasteurization of dairy products, remains the mainstay of reducing
zTB risk to humans, while new point of care diagnostics will help to
detect and appropriately treat human cases.
Lipman et al. (2021) highlight that pulmonary disease caused
by non-tuberculous mycobacteria (NTM) is often missed, is
difficult to treat successfully in an often frail population with
other chronic conditions such as bronchiectasis and COPD, is on the
rise globally, and results in significant morbidity and even
mortality. They identify and discuss key issues in NTM manage-
ment. In addition to the need for research into epidemiology,
immunology and treatment, they recommend an 8-point planesistant M. tuberculosis could ultimately lead to better treatment
utcomes. The additional value WGS provides in inferring drug
esistance is discussed by Lam et al. (2021). They sequenced
enomes from all M. tuberculosis isolates in NSW, Australia,
ollected between 2016 and 2019 and tracked the prevalence of
rug resistance and circulation of predominant M. tuberculosis2
including greater use of patient and clinician networks to educate
primary and secondary care clinicians and promote a multidisci-
plinary team approach with shared patient-clinician decision
making throughout care. They also call for co-ordinated patient-
focused research to improve what is often a limited evidence base
to guide management.
A. Zumla, J. Chakaya, M. Khan et al. International Journal of Infectious Diseases xxx (xxxx) xxx–xxx
G Model
IJID-5248; No. of Pages 5Nachega et al. (2021b) re-ignite the century old controversies
on the Bacille Calmette–Guérin (BCG) vaccine, which is yet again a
focus of global attention—this time due to the global COVID-19
pandemic caused by SARS-CoV-2) Their viewpoint focusses on the
assumptions, knowns, unknowns and need for developing an
accurate scientific evidence base for suggestions of potential cross-
protection against SARS-CoV-2 infection. Recent studies have
shown that human CD4+ and CD8+ T-cells primed with a BCG-
derived peptide developed high reactivity to its corresponding
SARS-CoV-2-derived peptide. Furthermore, BCG vaccine has been
shown to substantially increase interferon-gamma (IFN-g) pro-
duction and its effects on CD4+ T-cells and these nonspecific
immune responses could be harnessed as cross protection against
severe forms of COVID-19. They highlight that there are numerous
clinical trials in progress to determine the effectiveness of BCG
vaccination for prevention of SARS-CoV-2 infection or to reduce
morbidity and mortality associated with COVID- 19. Data from
ongoing BGG trials may shed light on the mechanisms underlying
BCG-mediated immunity and could lead to improved efficacy,
increased tolerance of treatment, and identification of benefits
combining BCG and COVID-19 vaccines, or other adjunct immu-
notherapies.
There are several ongoing studies which are defining the
interactions between COVID-19 and TB. Petrone et al. (2021)
evaluated IFN-g levels in whole blood after stimulation with Mtb
antigens in the Quantiferon-Plus format or with peptides derived
from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S). They
demonstrated for the first time that COVID-19 patients, either with
TB or LTBI, have a low ability to build an immune response to SARS-
CoV-2 while retaining the ability to respond to Mtb-specific
antigens. These results may have important implications for the
clinical management of COVID-19 individuals coinfected with Mtb.
Fatima et al. (2021) focus on TB control in Pakistan and discuss
the importance of a multi-pronged approach for building better TB
controlsystemsto copewith the effectsofCOVID-19. As inallhigh-TB
endemic countries, COVID-19 is impacting negatively in Pakistan.
The COVID-19 has provided an opportunity in country to introduce
some adaptations to bring TB care closer to communities, increased
investments in human resources and addressing stigma, and
implementation of telemedicine systems for follow-up and con-
sultations. Global health inequities driving TB epidemiology,
including the environment and climate control, gender, age, socio-
economic status, and wealth as well as resource distribution, need to
be addressed by multiple approaches and sectors.
The WHO 2020 global TB Report estimates that in 2019 there
were an estimated 500,000 cases of multi-drug resistant TB (MDR-
TB) of which only 186,772 MDR-TB cases were diagnosed, and
positive treatment outcomes were achieved in 57% of them. These
data highlight the need for accelerating and improving MDR-TB
screening, diagnostic, treatment and patient follow-up services.
Issayeva et al. (2021) present the first study from Kazahstan on
culture conversion at six months in patients receiving bedaquiline-
and delamanid-containing regimens for the treatment of MDR-TB.
Tiberi et al. (2021) emphasize that the direct and indirect
negative impacts of COVID-19 on health services overall, including
national TB programs and TB services add further to longstanding
challenges for tackling MDR-TB such as availability of budgets,
rollout of TB diagnostics and TB drugs. Implementation of latest
WHO guidelines for MDR-TB, in light of COVID-19 disruption of TB
services will be difficult and, it is anticipated the numbers of MDR-
rapid diagnosis, quality treatment and follow up, and ensuring
availability of quality, regular supply of cost-free TB drugs (for both
DS-TB and MDR-TB) through improved procurement and distribu-
tion of TB drugs.
Sahu et al. (2021) remind us that it has been over two years
since global leaders signed the UN General Assembly high level
meeting on TB (UNGA-HLM-TB) declaration which committed to
mobilize 15 billion USD per annum for TB,13 billion USD for TB care
and 2 billion USD per annum for TB R&D (UNGA, 2018). They point
out that the follow up October 21, 2020 UN Secretary-General
report (UNGA, 2020) on progress towards implementation of the
UNHLM political declaration on TB stresses that although high-
level commitments and targets had galvanized global and national
progress towards ending TB, urgent and more ambitious invest-
ments and actions were required, especially in lieu of the COVID-19
pandemic where associated public health measures and travel
restrictions, have disrupted health services universally. The report
sets out 10 priority recommendations to get the world on track to
reach agreed targets by 2022. Importantly, all countries should
signup to these ten priority recommendations and the Global Fund
needs to increase its current commitment to mitigating the impact
of COVID-19 on TB services (Global Fund, 2020). Additional
supplementary measures and resources are required to reduce the
accumulating pool of undetected people with TB. These should
include ramped-up active case-finding with intensive community
engagement and contact tracing to sustain awareness of recogniz-
ing and responding to symptoms suggestive of TB, using digital
technology and other diagnostic tools, and an uninterrupted
supply of quality TB drugs and care for all people with TB (Stop TB
Partnership, 2020).
On World TB Day 2021, every political and community leader,
and funding agency must get the message that it is time to reduce
global inequities as we work towards a TB free world. While there
is a continued need to develop new prevention and treatment tools
for TB, obtaining the resources required for implementation of
current TB diagnostic and management tools could significantly
advance TB control efforts. World leaders need to urgently address
and reverse the socio-economic and health services impact of the
COVID-19 pandemic. As COVID-19 vaccines and public health
measures start to have an effect on slowing down the COVID-19
outbreak, every effort must be made by to ensure that health
services and prevention programs for TB are not compromised. The
commitment of western governments to the rapid development
and rollout of COVID-19 vaccines is commendable, but it is
important to ensure that no-one is ‘left behind’. It’s now time for
them to invest with equal commitment to ending the TB epidemic.
Reality showed us that it can be achieved, if there is serious
political will which is translated into measurable, tangible actions
resulting in impactful deliverables.
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